Diabetes is a complex metabolic disorder affecting glucose regulation in the body. Chronic hyperglycaemia is linked to organ failure and is closely associated with atherosclerotic cardiovascular disease. Therapies targeting both diabetes and atherosclerosis are promising. Diabetes is classified into type 1 (T1D) and type 2 (T2D), with T1D involving autoimmune destruction of pancreatic beta cells and T2D involving insulin resistance. Inflammation plays a significant role in both types, contributing to metabolic disorders and disease progression. Research highlights the importance of targeting inflammatory pathways to prevent and control diabetes. In T1D, inflammation involves immune cells like T cells, B cells, and macrophages, leading to beta cell destruction. In T2D, obesity and adipose tissue inflammation contribute to insulin resistance and beta cell dysfunction. Gut microbiota also influences diabetes through inflammatory pathways. Anti-inflammatory treatments, such as monoclonal antibodies and vitamin D, are being explored. Current therapies for T2D have anti-inflammatory effects, and future research focuses on combined suppression of inflammatory pathways. Inflammation is a key factor in diabetes pathogenesis, and targeting it offers potential for improved prevention and treatment.Diabetes is a complex metabolic disorder affecting glucose regulation in the body. Chronic hyperglycaemia is linked to organ failure and is closely associated with atherosclerotic cardiovascular disease. Therapies targeting both diabetes and atherosclerosis are promising. Diabetes is classified into type 1 (T1D) and type 2 (T2D), with T1D involving autoimmune destruction of pancreatic beta cells and T2D involving insulin resistance. Inflammation plays a significant role in both types, contributing to metabolic disorders and disease progression. Research highlights the importance of targeting inflammatory pathways to prevent and control diabetes. In T1D, inflammation involves immune cells like T cells, B cells, and macrophages, leading to beta cell destruction. In T2D, obesity and adipose tissue inflammation contribute to insulin resistance and beta cell dysfunction. Gut microbiota also influences diabetes through inflammatory pathways. Anti-inflammatory treatments, such as monoclonal antibodies and vitamin D, are being explored. Current therapies for T2D have anti-inflammatory effects, and future research focuses on combined suppression of inflammatory pathways. Inflammation is a key factor in diabetes pathogenesis, and targeting it offers potential for improved prevention and treatment.